🔗 Share this article

While America proceeds with unprecedented revisions to its immunization recommendations, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccines during the pandemic and has focused upon potential deaths following COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Program

Agency leaders had intended to announce major changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of alignment with a large portion of the international standard with no evidence for benefit. The announcement has been delayed until the next year.

In place of Vinay Prasad, Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for ending specific pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

To date comments, she has continued to focus on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Qualifications

Høeg has no apparent track record in medication creation, regulation or leadership, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that previous people who led the center have had.”

This division has an immense workload at the FDA, Woodcock emphasized.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and all of those need to be supervised,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the position, which supervises in excess of 5,000 staff members. “It’s a enormous management job, if you do it right,” the former official said.

Official Statement and Contentious Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “questions rely on inaccurate presumptions”.

“This background matches the responsibilities of her role,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a contentious one-day drug-approval program that allegedly concerned her former heads. “How are these therapies being selected for this voucher program? Who makes the decisions?” Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards more relaxed regulations of pharmaceuticals, with the exception of vaccines.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, history, critics observe. She authored a research paper using unverified volunteer-provided data to determine the incidence of myocarditis following Covid vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are riskier than they are.

Included in her “wish list” for the incoming administration featured altering rules for recently developed shots and discontinuing “optional” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has reportedly proposed excluding young men from getting Covid vaccinations.

“She is an all-around true believer who starts off with her beliefs and reverse-engineers to retrofit the science in a very misleading, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other contrarians, {like|